This paper is in the following e-collection/theme issue:

Health Services Research in Oncology (61) Equity and Digital Divide (385) Cost-Effectiveness and Economics (362) Vulnerable Populations in Health Research (245)

Published on in Vol 12 (2026)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/68101, first published .
Financial Toxicity of Hematologic Malignancy Therapies, Including Cellular Therapy and Its Impact on Access to Care: Prospective Pilot Study

Financial Toxicity of Hematologic Malignancy Therapies, Including Cellular Therapy and Its Impact on Access to Care: Prospective Pilot Study

Financial Toxicity of Hematologic Malignancy Therapies, Including Cellular Therapy and Its Impact on Access to Care: Prospective Pilot Study

Authors of this article:

Lemchukwu Amaeshi1, 2 Author Orcid Image ;   Lauren Laufer1, 3 Author Orcid Image ;   Kateryna Fedorov4, 5 Author Orcid Image ;   Alex Sisto1, 6 Author Orcid Image ;   David Levitz4 Author Orcid Image ;   Rosmi Mathew1 Author Orcid Image ;   Karen Wright1 ;   Dennis Cooper4 Author Orcid Image ;   Mendel Goldfinger4 Author Orcid Image ;   Ioannis Mantzaris4 Author Orcid Image ;   R Alejandro Sica4 Author Orcid Image ;   Kira Gritsman4 Author Orcid Image ;   Marina Konopleva4, 7 Author Orcid Image ;   Ridhi Gupta4 Author Orcid Image ;   Noah Kornblum4 Author Orcid Image ;   Chenxin Zhang2 Author Orcid Image ;   Mimi Kim2 Author Orcid Image ;   Amit Verma4 Author Orcid Image ;   Bruce Rapkin1, 2 Author Orcid Image ;   Aditi Shastri4 Author Orcid Image ;   Nishi Shah4 Author Orcid Image
Article Authors Cited by Tweetations Metrics
All Time | Last Month | Last Six Months | Last Year
There are currently no tweets available for this article within the specified range.